Skip to main content
Erschienen in:

14.07.2016 | ORIGINAL ARTICLE

Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine

verfasst von: Giuseppe M. C. Rosano, Cristiana Vitale, Maurizio Volterrani

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Percutaneous coronary intervention and anti-anginal medications have similar prognostic effectiveness in patients with chronic stable angina. The choice of optimal medical therapy for the management of chronic angina is of pivotal importance in patients with stable ischemic heart disease. The most commonly used anti-anginal agents have demonstrated equivalent efficacy in improving patient reported ischemic symptoms and quantitative exercise parameters. With regards to mortality, beta-blockers are beneficial only in the setting of depressed left ventricular systolic function after a recent myocardial infarction. Recent evidence suggests the lack of any benefit of beta-blockers in patients with preserved systolic function, even in the setting of prior myocardial infarction.
Ranolazine is a non-haemodynamic anti-anginal agent. It is effective as adjunctive therapy in patients with chronic stable angina whose symptoms are un-adequately controlled by conventional treatment. The clinical development program of ranolazine has shown that the drug improves exercise performance, decreases angina and use of sublingual nitrates, compared to placebo. Ranolazine is well tolerated with neutral effect on haemodynamics. Besides its role in chronic stable angina, ranolazine has the potential for development in a number of other cardiovascular and non-cardiovascular conditions in the future.
Literatur
1.
Zurück zum Zitat Task Force Members, Montalescot G, Sechtem U, Achenbach S, et al 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003. Task Force Members, Montalescot G, Sechtem U, Achenbach S, et al 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.
2.
Zurück zum Zitat Scarborough P, Bhatnagar P, Wickramasinghe K, Smolina K, Mitchell C, Rayner M. Coronary heart disease statistics 2010. British Heart Foundation 2010. Scarborough P, Bhatnagar P, Wickramasinghe K, Smolina K, Mitchell C, Rayner M. Coronary heart disease statistics 2010. British Heart Foundation 2010.
3.
Zurück zum Zitat Rosano GM, Fini M, Caminiti G, Barbaro G. Cardiac metabolism in myocardial ischemia. Curr Pharm Des. 2008;14(25):2551–62.CrossRefPubMed Rosano GM, Fini M, Caminiti G, Barbaro G. Cardiac metabolism in myocardial ischemia. Curr Pharm Des. 2008;14(25):2551–62.CrossRefPubMed
4.
Zurück zum Zitat Rosano GM, Collins P. Gender differences in treatment of cardiovascular disease: a task force on gender of the ESC proposal on gender specific studies in cardiovascular pharmacology. Fundam Clin Pharmacol. 2010;24(6):662–3.CrossRefPubMed Rosano GM, Collins P. Gender differences in treatment of cardiovascular disease: a task force on gender of the ESC proposal on gender specific studies in cardiovascular pharmacology. Fundam Clin Pharmacol. 2010;24(6):662–3.CrossRefPubMed
5.
Zurück zum Zitat Boden W, O‘Rourke R, Teo K, et al. Optimal medical therapy with or without PCI for stable coronary disease: the COURAGE trial. N Engl J Med. 2007;356:1503–16.CrossRefPubMed Boden W, O‘Rourke R, Teo K, et al. Optimal medical therapy with or without PCI for stable coronary disease: the COURAGE trial. N Engl J Med. 2007;356:1503–16.CrossRefPubMed
7.
Zurück zum Zitat Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J. 2004;6(suppl A):A13–7. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J. 2004;6(suppl A):A13–7.
9.
Zurück zum Zitat Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res. 1992;71:1231–41.CrossRefPubMed Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res. 1992;71:1231–41.CrossRefPubMed
10.
Zurück zum Zitat Wu J, Corr PB. Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes. Am J Phys. 1994;266:H1034–46. Wu J, Corr PB. Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes. Am J Phys. 1994;266:H1034–46.
12.
Zurück zum Zitat Huang B, El Sherif T, Gidh-Jain M, et al. Alterations of sodium canne kinetics and gene expression in the postinfarction remodeled myocardium. J Cardiovasc Electrophysiol. 2001;12:218–25.CrossRefPubMed Huang B, El Sherif T, Gidh-Jain M, et al. Alterations of sodium canne kinetics and gene expression in the postinfarction remodeled myocardium. J Cardiovasc Electrophysiol. 2001;12:218–25.CrossRefPubMed
13.
Zurück zum Zitat Murphy E, Perlman M, London RE, Steenbergen C. Amiloride delays the ischemia-induced rise in cytosolic free calcium. Circ Res. 1991;68:1250–8.CrossRefPubMed Murphy E, Perlman M, London RE, Steenbergen C. Amiloride delays the ischemia-induced rise in cytosolic free calcium. Circ Res. 1991;68:1250–8.CrossRefPubMed
14.
Zurück zum Zitat Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in Guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004;44:192–9.CrossRefPubMed Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in Guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004;44:192–9.CrossRefPubMed
15.
Zurück zum Zitat Undrovinas AI, Undrovinas NA, Belardinelli L. Ranolazine inhibits late sodium current in isolated left ventricular myocytes of dogs with heart failure. J Am Coll Cardiol. 2004;43:178A.CrossRef Undrovinas AI, Undrovinas NA, Belardinelli L. Ranolazine inhibits late sodium current in isolated left ventricular myocytes of dogs with heart failure. J Am Coll Cardiol. 2004;43:178A.CrossRef
16.
Zurück zum Zitat Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904–10.CrossRefPubMedPubMedCentral Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904–10.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Fraser H, Belardinelli L, Wang L, et al. Inhibition of late INa by ranolazine reduces Ca2 overload and LV mechanical dysfunction in ejecting rat hearts. Eur Heart J. 2005;26(abstract suppl.):414. Fraser H, Belardinelli L, Wang L, et al. Inhibition of late INa by ranolazine reduces Ca2 overload and LV mechanical dysfunction in ejecting rat hearts. Eur Heart J. 2005;26(abstract suppl.):414.
18.
Zurück zum Zitat Gralinski MR, Black SC, Kilgore KS, et al. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res. 1994;28:1231–7.CrossRefPubMed Gralinski MR, Black SC, Kilgore KS, et al. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res. 1994;28:1231–7.CrossRefPubMed
19.
Zurück zum Zitat Maruyama K, Hara A, Hashizume H, et al. Ranolazine attenuates palmitoyl-L-carnitine induced mechanical and metabolic derangement in the isolated, perfused rat heart. J Pharm Pharmacol. 2000;52:709–15.CrossRefPubMed Maruyama K, Hara A, Hashizume H, et al. Ranolazine attenuates palmitoyl-L-carnitine induced mechanical and metabolic derangement in the isolated, perfused rat heart. J Pharm Pharmacol. 2000;52:709–15.CrossRefPubMed
20.
Zurück zum Zitat Chaitman BR, Skettino SL, Parker JO, Ramos H-VA, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–82.CrossRefPubMed Chaitman BR, Skettino SL, Parker JO, Ramos H-VA, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–82.CrossRefPubMed
21.
Zurück zum Zitat Chaitman BR, Pepine CJ, Parker JO, for the Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. A randomized controlled trial. JAMA. 2004;291:309–16.CrossRefPubMed Chaitman BR, Pepine CJ, Parker JO, for the Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. A randomized controlled trial. JAMA. 2004;291:309–16.CrossRefPubMed
22.
Zurück zum Zitat Stone PH, Gratsiansky NA, Blokhin A, Huang I-Z, Meng L, for the ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial. J Am Coll Cardiol. 2006;48:566–75.CrossRefPubMed Stone PH, Gratsiansky NA, Blokhin A, Huang I-Z, Meng L, for the ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial. J Am Coll Cardiol. 2006;48:566–75.CrossRefPubMed
23.
Zurück zum Zitat Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, for the MERLIN-TIMI 36 Trial Investigators, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERLIN-TIMI 36 Randomized Trial. JAMA. 2007;297:1775–83.CrossRefPubMed Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, for the MERLIN-TIMI 36 Trial Investigators, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERLIN-TIMI 36 Randomized Trial. JAMA. 2007;297:1775–83.CrossRefPubMed
24.
Zurück zum Zitat Kosiborod M, Arnold SV, Spertus JA, et al. The TERISA study (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina). J Am Coll Cardiol. 2013;61(20):2038–45.CrossRefPubMed Kosiborod M, Arnold SV, Spertus JA, et al. The TERISA study (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina). J Am Coll Cardiol. 2013;61(20):2038–45.CrossRefPubMed
25.
Zurück zum Zitat Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, Davidson-Ray L, Witkowski A, Mulkay AJ, Osmukhina A, Farzaneh-Far R, Ben-Yehuda O, Stone GW, Ohman EM. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the ranolazine for incomplete vessel revascularization (RIVER-PCI) trial. Circulation. 2016;133(1):39–47.CrossRefPubMed Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, Davidson-Ray L, Witkowski A, Mulkay AJ, Osmukhina A, Farzaneh-Far R, Ben-Yehuda O, Stone GW, Ohman EM. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the ranolazine for incomplete vessel revascularization (RIVER-PCI) trial. Circulation. 2016;133(1):39–47.CrossRefPubMed
26.
Zurück zum Zitat Savarese G, Rosano G, D’Amore C, et al. Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis. Int J Cardiol. 2013;169(4):262–70.CrossRefPubMed Savarese G, Rosano G, D’Amore C, et al. Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis. Int J Cardiol. 2013;169(4):262–70.CrossRefPubMed
27.
Zurück zum Zitat Pettus J, McNabb B, Eckel RH, Skyler JS, Dhalla A, Guan S, Jochelson P, Belardinelli L, Henry RH. The effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin. Diabetes Obes Metab. 2016;18(5):463–74.CrossRefPubMed Pettus J, McNabb B, Eckel RH, Skyler JS, Dhalla A, Guan S, Jochelson P, Belardinelli L, Henry RH. The effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin. Diabetes Obes Metab. 2016;18(5):463–74.CrossRefPubMed
28.
Zurück zum Zitat Hidalgo-Vega A, Ramos-Goñi JM, Villoro R. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain. Eur J Health Econ. 2013;15(9):917–25. Hidalgo-Vega A, Ramos-Goñi JM, Villoro R. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain. Eur J Health Econ. 2013;15(9):917–25.
Metadaten
Titel
Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine
verfasst von
Giuseppe M. C. Rosano
Cristiana Vitale
Maurizio Volterrani
Publikationsdatum
14.07.2016
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 4/2016
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-016-6674-1

Weitere Artikel der Ausgabe 4/2016

Cardiovascular Drugs and Therapy 4/2016 Zur Ausgabe

Neu im Fachgebiet Kardiologie

Aggressive Blutdrucksenkung bei Risikopersonen?

12.07.2024 Arterielle Hypertonie Nachrichten

Geht es nach einer aktuellen chinesischen Studie, ist die Einstellung des systolischen Blutdrucks bei Risikopersonen auf Werte unter 120 mmHg mit weniger kardiovaskulären Ereignissen assoziiert als die Senkung auf Werte unter 140 mmHg.

Mehr Komplikationen beim akuten Koronarsyndrom ohne klassische Risikofaktoren

11.07.2024 Akutes Koronarsyndrom Nachrichten

Ein steigender Anteil von Personen mit akutem Koronarsyndrom (ACS) weist keine modifizierbaren Risikofaktoren auf. Wie sich das auf die Prognose auswirkt, wurde anhand eines australischen PCI-Registers untersucht. 

Taugen Risikoscores für Schlaganfall und Blutungen auch bei Krebskranken?

Britische Registerdaten sprechen dafür, dass sich die Blutungsrisikoprädiktion bei Personen mit Vorhofflimmern, die zugleich an Krebs leiden, nicht einfach aus Kohorten ohne Krebs übertragen lässt.

Bewusstsein während Reanimation – gibt es "typische" Fälle?

10.07.2024 Kardiopulmonale Reanimation Nachrichten

Australische Rettungsdienstdaten deuten darauf hin, dass sich Fälle, in denen eine laufende Reanimation Anzeichen von Bewusstsein induziert, von anderen Wiederbelebungsfällen unterscheiden könnten. Etwa mit Blick auf die Überlebenschancen.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.